Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer

Journal of the National Cancer Institute

Volumn 109, Issue 1, 2017, Pages

  Bense, Rico D ^a   Sotiriou, Christos ^b   Piccart Gebhart, Martine J ^b   Haanen, John B A G ^c   Van Vugt, Marcel A T M ^a   De Vries, Elisabeth G E ^a   Schroder, Carolien P ^a   Fehrmann, Rudolf S N ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b JULES BORDET INSTITUTE   (Belgium)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ERBB2 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; TRANSCRIPTOME;

ADULT; BREAST CANCER; CD8+ T LYMPHOCYTE; CELL COMPOSITION; COMPUTER MODEL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; MACROPHAGE; MAJOR CLINICAL STUDY; MAST CELL; NATURAL KILLER T CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; BREAST TUMOR; CHEMISTRY; COMPUTER SIMULATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; SURVIVAL RATE;

BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; COMPUTER SIMULATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MAST CELLS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, ESTROGEN; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTOME;

EID: 85014873742     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw192     Document Type: Review

References (52)

1. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007;13(4):1198-1207.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793):771-784.
3. Emens L, Braiteh F, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2014;abstr PD1-6.
4. Nanda R, Chow L, Dees E, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. San Antonio Breast Cancer Symposium 2014;abstr S1-09.
5. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860-867.
6. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8): 1544-1550.
7. Salgado R, Denkert C, Campbell C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab. JAMA Oncol. 2015;1(4):448-454.
8. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113.
9. Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132(3):793-805.
10. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983-991.
11. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast cancer. Cancer Res. 1996;56(20):4625-4629.
12. Campbell MJ, Tonlaar NY, Garwood ER, et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011;128(3):703-711.
13. Zhang Y, Cheng S, Zhang M, et al. High-infiltration of tumor-associated macrophages predicts unfavorable clinical outcome for node-negative breast cancer. PLoS One. 2013;8(9):1-8.
14. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158-5165.
15. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007;8(8):R157.
16. Perez EA, Thompson EA, Ballman KV, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. J Clin Oncol. 2015;33(7):701-708.
17. Gu-Trantien C, Loi S, Garaud S, et al. CD4 follicular helper T-cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):1-20.
18. McKinney EF, Lyons PA, Carr EJ, et al. A CD8 T-cell transcription signature predicts prognosis in autoimmune disease. Nat Med. 2010;16(5): 586-591.
19. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453-457.
20. Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41(D1):991-995.
21. Crijns APG, Fehrmann RSN, De Jong S, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009;6(2): 0181-0193.
22. Heijink DM, Fehrmann RSN, de Vries EGE, et al. A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer. Oncogene. 2011;30(17):2026-2036.
23. Fehrmann RSN, Karjalainen JM, Krajewska M, et al. Gene expression analysis identifies global gene dosage sensitivity in cancer. Nat Genet. 2015;47(2): 115-125.
24. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-2795.
25. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013.
26. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-8423.
27. Parker JS, Mullins M, Cheung MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
28. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.
29. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767.
30. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):1-12.
31. Ignatiadis M, Singhal SK, Desmedt C, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol. 2012;30(16):1996-2004.
32. Korn EL, Troendle JF, McShane LM, Simon R. Controlling the number of false discoveries: application to high-dimensional genomic data. J Stat Plan Inference. 2014;124(2):379-398.
33. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T-cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373-5380.
34. Liu F, Lang R, Zhao J, et al. CD8 cytotoxic T-cell and FOXP3 regulatory T-cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130(2):645-655.
35. Liu S, Foulkes WD, Leung S, et al. Prognostic significance of FOXP3 tumorinfiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014;16(5):1-12.
36. Merlo A, Casalini P, Carcangiu ML, et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009;27(11):1746-1752.
37. Aruga T, Suzuki E, Saji S, et al. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favourable anti-tumor response in patients with breast cancer. Oncol Rep. 2011;25(1): 223-230.
38. Romano E, Kusio-Kobialka M, Foukas PG, et al. Ipilimumab-dependent cellmediated cytotoxicity of regulatory T-cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112(19):6140-6145.
39. Diab A, McArthur H, Solomon S, Sacchin I, Comstock C, Maybody M. A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer. J Clin Oncol. 2014;32;5s(suppl; abstr 1098).
40. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549-555.
41. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231-237.
42. Nywening TM, Wang-Gillam A, Sanford DE, et al. Targeting tumourassociated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651-662.
43. Aaltomaa S, Lipponen P, Palpinaho S, Kosma V. Mast cells in breast cancer. Anticancer Res. 1993;13(3):785-788.
44. Dabiri S, Huntsman D, Makretsov N, et al. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol. 2004;17(6):690-695.
45. Rajput A, Turbin D, Cheang M, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: A study of 4,444 cases. Breast Cancer Res Treat. 2008;107(2):249-257.
46. Rovere F Della, Granata A, Familiari D, D'Arrigo G, Mondello B, Basile G. Mast cells in invasive ductal breast cancer: Different behavior in high and minimumhormone-receptive cancers. Anticancer Res. 2007;27(4B):2465-2471.
47. Khazaie K, Blatner NR, Khan MW, et al. The significant role of mast cells in cancer. Cancer Metastasis Rev. 2011;30(1):45-60.
48. Crome S, Lang P, Lang K, Ohashi P. Natural killer cells regulate diverse T-cell responses. Trends Immunol. 2013;34(7):342-349.
49. McKinney EF, Lee JC, Jayne DRW, Lyons PA, Smith KGC. T-cell exhaustion, costimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612-616.
50. Poschke I, De Boniface J, Mao Y, Kiessling R. Tumor-induced changes in the phenotype of blood-derived and tumor-associated T-cells of early stage breast cancer patients. Int J Cancer. 2012;131(7):1611-1620.
51. Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 2016; in press.
52. Rugo H, Delord J-P, Im S-A, et al. Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor-positive (ER)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. San Antonio Breast Cancer Symposium 2015;abstr S5-S07.